UCSF adult and pediatric clinical trials

UCSF Brain Tumor Center Clinical Trials

Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors. 

Identify Relevant Clinical Trials
Clinical Trial Phase
Intervention Model
Treatment Modality
Which of the following treatments has the patient already received?*
Genetic Features*
  • Recruiting Recruiting
  • Pediatrics Pediatrics
  • On Hold On Hold
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Summary

This observational study will evaluate an assay using a patient’s own biopsy or resected tumor tissue to assess tissue response to various therapeutic agents.

Recruiting
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
DCC-2618 is an orally administered drug designed to inhibit the activity of proteins called KIT and PDGFRα. KIT and PDGFRα are proteins that are mutated or abnormally active in variety of cancer cell types; when mutated, these proteins can increase tumor cell proliferation and resistance to chemotherapy.
Recruiting
Conditions
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Atypical Teratoid / Rhaboid Tumor (AT/RT)
Ependymoma
Medulloblastoma
Brainstem Glioma
Diffuse Midline Glioma
This phase I clinical trial will evaluate the safety and tolerability of a single tumor injection of Ad-RTS-hIL-12 given with veledimex, for pediatric patients with brain tumors.
Recruiting
Conditions
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Brainstem Glioma
Diffuse Midline Glioma
Atypical Teratoid / Rhaboid Tumor (AT/RT)
Ependymoma
Medulloblastoma
Summary

The purpose of this Phase I/II clinical trial is to evaluate the dosage, safety and efficacy of pembrolizumab in treating pediatric participants with any of the following types of cancer:

Recruiting
Conditions
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Brainstem Glioma
Diffuse Midline Glioma
Atypical Teratoid / Rhaboid Tumor (AT/RT)
Subependymal giant cell astrocytoma (grade I)
Medulloblastoma
Choroid Plexus Tumors
The purpose of this Phase I clinical trial is to evaluate the safety and efficacy of the drug ramucirumab, in treating children with recurrent or refractory solid tumors, including CNS tumors.
Recruiting
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
Anaplastic astrocytoma (grade III)
Diffuse astrocytoma (grade II)
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Ependymoma
Oligodendroglioma
This phase I clinical trial will evaluate the safety, efficacy and clinical activity of BGB-290 in combination with temozolomide, for treating adolescents and young adults with IDH1/2-mutant glioma (grades I-IV).
Recruiting
Conditions
Glioma
Astrocytoma
Diffuse Midline Glioma
Brainstem Glioma
This Phase I clinical trial will assess the safety and preliminary efficacy of delivering nal-IRI (a specialized formulation of irinotecan, a chemotherapy drug) directly into the brain through convection enhanced delivery, in treating children with newly diagnosed DIPG.
Recruiting
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Pleomorphic xanthoastrocytoma (grades II-III)
Ependymoma
Oligodendroglioma
This pilot trial will evaluate an individualized treatment approach for children and young adults with high-grade glioma, using proteomic, transcriptomic, and genomic profiling to provide a personalized treatment plan.
Recruiting
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
This phase I trial will evaluate an individualized treatment approach, based on the results of the UCSF 500 Cancer Gene Panel, for patients with surgically resectable recurrent glioblastoma.
Recruiting

Stay Informed